Precision oncology approach towards understanding prostate cancer lineage plasticity

Von l. nach r.: Simone de Brot, Mark Rubin

Principal Investigator
Prof. Dr. Mark Andrew Rubin,  Precision Oncology Research Group, Department for Biomedical Research, University of Bern. For more information, please visit the website.

Dr. Simone de Brot, Vetsuisse Faculty, Institute of Animal Pathology. 

Prostate cancer (PCa) is a leading cause of morbidity and mortality in men. As it is driven by the male hormone -androgen-, the first-line treatment for advanced metastatic PCa is based on androgen deprivation. Although initially effective, the treatment ultimately fails and tumors progress. Second-line treatment with more potent anti-androgens delays progression; however, most tumors will eventually evolve into a lethal phenotype that does not depend on androgens.  This project focusing on this “off-target” therapy resistance has the potential to better understand cancer behavior, discover novel markers for cancer detection, and identify new strategies for a successful and personalized treatment.